Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
Want to see MAZE full AI Analyst Report?
MAZE Stock Chart & Stats
$28.09
--
Market closed
$28.09
--
Day’s Range― - ―
52-Week Range$9.83 - $53.65
Previous CloseN/A
VolumeN/A
Average Volume (3M)526.33K
Market Cap
$1.57B
Enterprise Value$1.24B
Total Cash (Recent Filing)$352.38M
Total Debt (Recent Filing)$61.22M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 18, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.75
Shares Outstanding55,345,260
10 Day Avg. Volume659,433
30 Day Avg. Volume526,332
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-15.79
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue61.86
Enterprise Value/Gross Profit67.21
Enterprise Value/Ebitda-10.35
Forecast
1Y Price Target
$70.00Price Target Upside149.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$22.22M
Bulls Say, Bears Say
Bulls Say
Genetics-driven Discovery PlatformMaze’s platform uses human genetics to identify causal disease pathways and develop small‑molecule modulators. This genetically anchored approach improves target validation and can raise the probability of clinical success, creating a durable scientific moat versus phenotype-only discovery models.
Extended Multi-year Cash RunwayThe $150M registered offering (net proceeds ~ $144.7M) materially extends liquidity into 2029, enabling multi-year clinical development of lead programs without immediate fundraising. A secured runway reduces near-term execution risk and allows focus on advancing MZE829 and MZE782 to meaningful milestones.
Low Financial Leverage And Equity CushionMaze’s balance sheet shows low debt relative to equity and a sizeable equity base, providing financial flexibility. Manageable leverage lowers refinancing pressure and supports continued R&D investment, giving the company structural resilience while it pursues clinical readouts.
Bears Say
Sustained Negative Cash FlowOperating and free cash flow remain deeply negative on a TTM basis, with cash burn closely tracking net losses. Persistent negative cash flow means the company must rely on capital markets or partners for funding until it achieves durable revenue or positive operating leverage.
Volatile Revenue And ProfitabilityMaze’s income history is inconsistent: an outlier profitable year (2024) contrasts with large recent losses and modest TTM revenue. This inconsistency signals execution and commercialization risk, making future revenue predictability and margin sustainability uncertain.
Reliance On External Financing (dilution Risk)While the recent equity raise secures near-term funding, continued reliance on equity financing risks shareholder dilution and dependence on capital market conditions. Structural reliance on raises until self-sustaining revenues emerge increases financial and execution risk over the medium term.
Maze Therapeutics, Inc. News
MAZE FAQ
What was Maze Therapeutics, Inc.’s price range in the past 12 months?
Maze Therapeutics, Inc. lowest stock price was $9.83 and its highest was $53.65 in the past 12 months.
What is Maze Therapeutics, Inc.’s market cap?
Maze Therapeutics, Inc.’s market cap is $1.57B.
When is Maze Therapeutics, Inc.’s upcoming earnings report date?
Maze Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 50 days.
How were Maze Therapeutics, Inc.’s earnings last quarter?
Maze Therapeutics, Inc. released its earnings results on May 12, 2026. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.577 by $0.127.
Is Maze Therapeutics, Inc. overvalued?
According to Wall Street analysts Maze Therapeutics, Inc.’s price is currently Undervalued.
Does Maze Therapeutics, Inc. pay dividends?
Maze Therapeutics, Inc. does not currently pay dividends.
What is Maze Therapeutics, Inc.’s EPS estimate?
Maze Therapeutics, Inc.’s EPS estimate is -0.72.
How many shares outstanding does Maze Therapeutics, Inc. have?
Maze Therapeutics, Inc. has 55,345,260 shares outstanding.
What happened to Maze Therapeutics, Inc.’s price movement after its last earnings report?
Maze Therapeutics, Inc. reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.577. Following the earnings report the stock price went up 4.577%.
Which hedge fund is a major shareholder of Maze Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MAZE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Maze Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$70.00 (149.20% Upside)
$70.00 (149.20% Upside)
Blogger Sentiment
Bullish
MAZE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 214.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 2.2%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
123.15%
12-Months-Change
Fundamentals
Return on Equity
-36.63%
Trailing 12-Months
Asset Growth
26.10%
Trailing 12-Months
Company Description
Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
MAZE Stock 12 Month Forecast
Average Price Target
$70.00
▲(149.20% Upside)
Technical Analysis
Ownership Overview
11.14% Insiders
5.52% Mutual Funds
67.03% Other Institutional Investors
9.34% Public Companies and
Individual Investors